恒定自然杀伤T细胞与肿瘤免疫治疗北大核心CSCD

恒定自然杀伤T细胞(i NKT)是T淋巴细胞的一个独特亚群,兼具自然杀伤(NK)细胞和T细胞特征,同时表达T细胞受体(TCR)和NK细胞表面标志。i NKT细胞被激活后,通过分泌细胞因子,活化其它免疫细胞参与先天性免疫和获得性免疫,在抗肿瘤免疫过程中发挥调节作用。在多种癌症患者体内,发现外周血中i NKT细胞的数量降低、功能减弱,进而导致临床治疗效果不佳。近年来,基础研究和早期临床试验结果表明,注射抗原递呈细胞或/和体外培养并活化的i NKT细胞,抗肿瘤免疫治疗效果显著。本文就i NKT细胞的分类及生物学特性,在肿瘤免疫治疗中的作用与其机制,以及其临床应用等进行综述。     

γδT细胞在肿瘤免疫治疗中的研究进展

癌症是威胁人类健康最主要的疾病之一,目前临床上主要采用的手术/放化疗联合治疗的疗效有限,因此如何进一步提高肿瘤临床疗效仍是巨大的挑战。免疫细胞过继是肿瘤治疗技术中迅速发展的一种生物治疗技术,通过输入自身或同种"抗肿瘤免疫效应细胞"达到直接杀伤肿瘤或增强机体自身细胞免疫功能的作用。由于γδT细胞对肿瘤细胞具有强有力的直接细胞毒性,并可与其他免疫细胞协同作用发挥其抗肿瘤活性,因而成为了细胞免疫治疗中新的研究热点。本文主要叙述了γδT细胞与肿瘤相关的基础研究及临床试验的最新进展。     

自然杀伤T细胞抗感染作用的研究进展

自然杀伤T细胞(NKT细胞)是一类与自然杀伤细胞具有共同表面标记的T细胞,可识别由CD1d呈递的糖脂类抗原。活化后的NKT细胞通过分泌多种细胞因子和趋化因子,增强树突细胞(DC)、T细胞、B细胞等多种免疫细胞的功能,在非特异与特异性免疫之间起桥梁作用。近年来研究发现,NKT细胞不仅在抗细菌感染中发挥重要作用,在抗病毒及抗寄生虫感染中也发挥一定作用。     

细胞因子诱导杀伤细胞过继免疫治疗恶性血液肿瘤的临床应用进展

细胞因子诱导的杀伤细胞(cytokine-induced killer cells,CIK cells)是将脐血、外周血和骨髓等不同来源的单个核细胞经适当浓度的IFN-γ、IL-2和CD3单抗等联合诱导后获得的异质细胞群。CIK细胞具有增殖能力强、溶瘤谱广、对耐药细胞株也有杀伤作用,且兼有T细胞强大的杀伤活性和NK细胞(nature killer cells)非主要组织相容性复合体(non-major histocompatibility complex,non-MHC)限制性的特点,使其在肿瘤治疗中具有广阔的临床应用前景。恶性血液肿瘤患者接受CIK细胞过继免疫治疗的生存时间延长,不良反应少,但仍面临许多问题。     

自然杀伤细胞和自然杀伤T细胞在动脉粥样硬化形成中的作用

动脉粥样硬化发生发展与免疫细胞参与的免疫反应密切相关,其中自然杀伤细胞主要是通过释放IFN-γ、穿孔素和颗粒酶等方式发挥生物学作用,自然杀伤T细胞通过释放多种细胞因子影响动脉粥样硬化形成,但其具体机制未明。本文就自然杀伤细胞和自然杀伤T细胞对动脉粥样硬化的影响做一综述,为动脉粥样硬化及其相关疾病的防治研究提供新的思路。     

自然杀伤T细胞抗胞内菌感染的研究进展

自然杀伤T细胞(NKT细胞)是免疫细胞中一类具有特定标记的T细胞亚群,能特异性识别南抗原呈递细胞表面CD1d分子所呈递的糖脂类抗原.活化后的NKT细胞能分泌多种细胞因子,参与机体的天然免疫和获得性免疫反应,还能直接杀伤靶细胞,具有效应细胞的功能.研究发现,NKT细胞在抗胞内菌感染中发挥着重要作用.     

树突状细胞与CIK细胞共培养诱生的DCCIK细胞群对肿瘤的杀伤作用

由树突状细胞(DC)与细胞因子诱导的同源杀伤细胞(CIK)的共培养诱生的细胞群(DCCIK)对肿瘤细胞的细胞毒活性的研究。DCCIK细胞体外杀伤肿瘤靶细胞A549(MTT法),效靶比为10∶1、5∶1时杀伤率分别为61%、52%。DCCIK细胞诱导培养3周后,效靶比为10∶1、5∶1时杀伤率分别为64%和56%。数据亦表明DCCIK细胞对靶细胞的杀伤优于CIK细胞。动物体内实验分荷瘤A549、BEL7404和A375三组,每组分(A)DCCIK 化疗、(B)单用化疗。治疗20天、35天后测量各组肿瘤消失率。结果显示:DCCIK 化疗的抑瘤效果明显好于单纯化疗。提示DCCIK细胞有临床应用前景。     

靶向 T 细胞共信号的肿瘤免疫治疗研究进展

T 细胞介导的肿瘤免疫至少需要 T 细胞受体和共刺激分子“双信号”参与的学说目前得到了广泛支持。共抑制或共刺激分子提供的 共信号决定了 T 细胞受体信号介导的免疫应答的最终效应。近年来,靶向共抑制分子如 CTLA-4 和 PD-1 开发的抗体药物在临床应用中获 得了巨大成功,使得肿瘤免疫治疗成为最令人瞩目的研究领域,并被美国《科学》杂志评为 2013 年度十大科学突破之首。肿瘤免疫治疗有 望成为与手术、放化疗和靶向治疗并驾齐驱的抗肿瘤主流治疗方案。针对共抑制分子 CTLA-4、PD-1、PD-L1 和共刺激分子 CD137,综述 其发挥免疫调节作用的分子机制及其相关靶向药物在肿瘤治疗方面的最新进展和应用。     

调节性T细胞与胶质瘤的免疫治疗

调节性T细胞（regulatory T cell,Treg）是一群具有抑制其它免疫细胞功能的起负性调控的细胞群. Treg细胞能抑制多种免疫细胞,如CD4+T和CD8+T淋巴细胞、NK细胞、B淋巴细胞以及树突状细胞的活化和增殖,是体内维持免疫系统稳定,防止出现自身免疫性疾病重要因素.最新研究表明,Treg细胞在肿瘤免疫逃逸中也发挥重要作用. 肿瘤细胞通过扩增或招募Treg细胞,抑制机体对肿瘤的免疫作用,由此可知,Treg细胞在肿瘤的发生和发展过程中发挥重要作用. 因此,抑制Treg细胞的活性和数量是包括胶质瘤在内的肿瘤免疫治疗有效的方式.     

iPSC-Derived Natural Killer Cells for Cancer Immunotherapy

The discovery of human pluripotent stem cells (PSCs) at the turn of the century opened the door to a new generation of regenerative medicine research. Among PSCs, the donors available for induced pluripotent stem cells (iPSCs) are greatest, providing a potentially universal cell source for all types of cell therapies including cancer immunotherapies using natural killer (NK cells). Unlike primary NK cells, those prepared from iPSCs can be prepared with a homogeneous quality and are easily modified to exert a desired response to tumor cells. There already exist several protocols to genetically modify and differentiate iPSCs into NK cells, and each has its own advantages with regards to immunotherapies. In this short review, we detail the benefits of using iPSCs in NK cell immunotherapies and discuss the challenges that must be overcome before this approach becomes mainstream in the clinic.     

自然杀伤细胞在肿瘤免疫治疗中的作用

自然杀伤(NK)细胞是人体先天免疫的核心组成部分,是肿瘤细胞免疫治疗和抗体免疫治疗的基础.NK细胞通过直接杀伤作用和释放细胞因子来共同控制肿瘤的生长和转移.目前,已开发出多种利用激活的NK细胞治疗肿瘤的方案.然而,癌症患者的NK细胞功能受损,抗癌能力下降,均限制了NK 细胞的临床疗效 .新的方案通过提高NK细胞的数量和杀伤功能来改善治疗效果. 利用体外长期激活、大规模培养临床使用的NK细胞是达成上述效果的最佳方法之一. 本综述讨论了NK细胞研究背景,NK细胞治疗的现状,尤其是体外培养扩增具有较强功能NK细胞的新方案.     

Assessment of T Cell Receptor Complex Expression Kinetics in Natural Killer Cells

Among the polypeptides that comprise the T cell receptor (TCR), only CD3ζ is found in Natural Killer (NK) cells, where it transmits signals from activating receptors such as CD16 and NKp46. NK cells are potent immune cells that recognize target cells through germline-encoded activating and inhibitory receptors. Genetic engineering of NK cells enables tumor-specific antigen recognition and, thus, has a significant promise in adoptive cell therapy. Ectopic expression of engineered TCR components in T cells leads to mispairing with the endogenous components, making a knockout of the endogenous TCR necessary. To circumvent the mispairing of TCRs or the need for knockout technologies, TCR complex expression has been studied in NK cells. In the current study, we explored the cellular processing of the TCR complex in NK cells. We observed that in the absence of CD3 subunits, the TCR was not expressed on the surface of NK cells and vice versa. Moreover, a progressive increase in surface expression of TCR between day three and day seven was observed after transduction. Interestingly, the TCR complex expression in NK92 cells was enhanced with a proteasome inhibitor (bortezomib) but not a lysosomal inhibitor (chloroquine). Additionally, we observed that the TCR complex was functional in NK92 cells as measured by estimating CD107a as a degranulation marker, IFNγ cytokine production, and killing assays. NK92 cells strongly degranulated when CD3ε was engaged in the presence of TCR, but not when only CD3 was overexpressed. Therefore, our findings encourage further investigation to unravel the mechanisms that prevent the surface expression of the TCR complex.     

自然杀伤细胞参与肝脏恶性肿瘤免疫逃逸研究进展

自然杀伤细胞是机体固有免疫系统重要组成部分,在肝脏等免疫器官中含量丰富,而且免疫表型、功能等表现出器官特异性。在正常情况下,靶细胞表面的配体与自然杀伤细胞表面的活化性受体直接结合并释放细胞毒性物质,诱导活化靶细胞凋亡程序,从而发挥抗感染、抗肿瘤作用。然而肿瘤细胞仍能够通过多种途径逃逸机体的免疫监视功能,研究认为肿瘤细胞抗原异常表达、肿瘤微环境中细胞因子及其他免疫细胞相互作用等因素所引起的自然杀伤细胞活性降低对于诱导肿瘤免疫逃逸起重要作用。本文综述了自然杀伤细胞在肝脏恶性肿瘤发生过程中参与免疫逃逸的机制及研究进展,以期为临床抗肿瘤免疫治疗的研究提供参考。     

CAR-NK细胞在癌症免疫治疗中的研究进展

自然杀伤(NK)细胞是一种重要的肿瘤杀伤性免疫细胞,在细胞免疫治疗中有着良好的应用前景。嵌合抗原受体(CAR)是一种人工修饰的融合蛋白,它可以通过胞外区特异性识别肿瘤并激活胞内区信号域。CAR-T细胞在临床中取得了巨大的成功,而NK细胞比T细胞在CAR其相对于T细胞的优势,并就NK细胞的来源、CAR-NK在临床中的应用及存在的挑战做简要综述。     

不孕症患者的子宫自然杀伤细胞、浆细胞与子宫内膜异位症的相关性

摘要 目的：探究不孕症患者的子宫自然杀伤细胞、浆细胞与子宫内膜异位症的相关性。方法：选择80例患有子宫内膜异位症的不孕症患者做为本研究的不孕症组和80例正常生育的健康女性做为本研究的健康组,对比分析两组患者人口学基本资料、子宫自然杀伤细胞（uNKs）、浆细胞（PC）水平、血清性激素水平、子宫内膜中血管内皮生长因子（VEGF）表达情况、免疫细胞水平。通过Person法分析不孕症患者的子宫自然杀伤细胞、浆细胞与子宫内膜异位症的相关性。结果：两组的BMI指数、流产史、吸烟史、饮酒史比较,差异有统计学意义（P<0.05）;不孕症组患者uNKs、抗苗勒氏管激素（AMH）和黄体生成素（LH）水平均显著高于健康组;PC、卵泡刺激素（FSH）、雌激素（Estrogen）和性激素结合球蛋白（SHBG）、VEGF阳性表达水平、CD4⁺、CD8⁺和CD4⁺/CD8⁺水平均显著低于健康组,差异有统计学意义（P<0.05）。另外,不孕症患者的uNKs与子宫内膜异位症存在显著的正相关关系（r=1.555,P<0.001）;PC与子宫内膜异位症存在显著的负相关关系（r=-3.778,P<0.001）。结论：不孕症患者的uNKs、PC参与不孕症的发生和发展过程,对女性子宫内膜异位症的诊断具有重要的参考意义。     

Natural Killer Cell Receptor+ T‐Lymphocytes in Normal and Helicobacter pylori‐Infected Human Gastric Mucosa

Background: Helicobacter pylori infection is associated with development of chronic inflammation and infiltration of immune cells into the gastric mucosa. As unconventional T‐lymphocytes expressing natural killer cell receptors are considered to play central roles in the immune response against infection, a study investigating their frequencies in normal and H. pylori‐infected gastric mucosa was undertaken. Materials and Methods: Flow cytometry was used to quantify T‐cells expressing the natural killer cell markers CD161, CD56, and CD94 in freshly isolated lymphocytes from the epithelial and lamina propria layers of gastric mucosa. Thirteen H. pylori‐positive and 24 H. pylori‐negative individuals were studied. Results: CD94⁺ T‐cells were the most abundant (up to 40%) natural killer receptor‐positive T‐cell population in epithelial and lamina propria layers of H. pylori‐negative gastric mucosa. CD161⁺ T‐cells accounted for about one‐third of all T‐cells in both compartments, but the lowest proportion were of CD56⁺ T‐cells. Compared with H. pylori‐negative mucosa, in H. pylori‐infected mucosa the numbers of CD161⁺ T‐cells were significantly greater (p = .04) in the epithelium, whereas the numbers of CD56⁺ T‐cells were lower (p = .01) in the lamina propria. A minor population (< 2%) of T‐cells in both mucosal layers of H. pylori‐negative subjects were natural killer T‐cells, and whose proportions were not significantly different (p > .05) to those in H. pylori‐infected individuals. Conclusions: The predominance, heterogeneity, and distribution of natural killer cell receptor‐positive T‐cells at different locations within the gastric mucosa reflects a potential functional role during H. pylori infection and warrants further investigation.     

Generation and Preclinical Characterization of an NKp80-Fc Fusion Protein for Redirected Cytolysis of Natural Killer (NK) Cells against Leukemia

The capacity of natural killer (NK) cells to mediate Fc receptor-dependent effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), largely contributes to their clinical application. Given that activation-induced C-type lectin (AICL), an identified ligand for the NK-activating receptor NKp80, is frequently highly expressed on leukemia cells, the lack of therapeutic AICL-specific antibodies limits clinical application. Here we explore a strategy to reinforce NK anti-leukemia reactivity by combining targeting AICL-expressing leukemia cells with the induction of NK cell ADCC using NKp80-Fc fusion proteins. The NKp80-Fc fusion protein we generated bound specifically to leukemia cells in an AICL-specific manner. Cell binding assays between NK and leukemia cells showed that NKp80-Fc significantly increased NK target cell conjugation. In functional analyses, treatment with NKp80-Fc clearly induced the ADCC effect of NK cells. NKp80-Fc not only promoted NK-mediated leukemia cell apoptosis in the early stage of cell conjugation but also enhanced NK cell degranulation and cytotoxicity activity in the late stage. The bifunctional NKp80-Fc could redirect NK cells toward leukemia cells and triggered NK cell killing in vitro. Moreover, NKp80-Fc enhanced the lysis of NK cells against tumors in leukemia xenograft non-obese diabetic/severe combined immunodeficiency mice. Taken together, our results demonstrate that NKp80-Fc potently amplifies NK cell anti-leukemia effects in vitro and in vivo through induction of the NK cell ADCC effect. This method could potentially be useful for molecular targeted therapy, and the fusion proteins may be a promising drug for immunotherapy of leukemia.     

肿瘤的细胞免疫治疗研究进展

随着抗原递呈机制与细胞对特异性抗原识别机制的揭示、众多重要的人细胞因子及其功能的发现、分子克隆与细胞克隆技术的发展,细胞免疫治疗日益受到重视,并成为肿瘤等疾病临床治疗新思路、新方法的研究热点,肿瘤的细胞免疫治疗技术也在近20年内得到了广泛深入的研究和临床实践。在此,我们简要综述近年来肿瘤的细胞免疫治疗研究进展。